Comparison of the Efficacy of Morning Versus Evening Administration of Telmisartan in Essential Hypertension
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Valsartan administration at bedtime as opposed to on wakening improves the sleep time–relative blood pressure decline toward a more dipper pattern without loss in 24-hour efficacy. Yet to be determined is whether this administration time-dependent efficacy is a class-related feature, characteristic of all angiotensin receptor blockers or specific only to valsartan. Terminal half-life is a major difference between angiotensin receptor blockers, being largest (≈24 hours) for telmisartan. This trial investigated the administration time-dependent antihypertensive efficacy of telmisartan. We studied 215 patients with hypertension (114 men and 101 women), 46.4±12.0 years of age, randomly assigned to receive telmisartan (80 mg/d) as a monotherapy either on awakening or at bedtime. Blood pressure was measured for 48 hours before and after 12 weeks of treatment. The significant blood pressure reduction after treatment was similar for both groups. Bedtime administration of telmisartan, however, was more efficient than morning dosing in reducing the nocturnal blood pressure mean. The sleep time–relative blood pressure decline was slightly reduced after telmisartan on awakening but significantly increased with bedtime dosing, thus reducing the prevalence of nondipping from baseline by 76%. Telmisartan administered at bedtime, as opposed to morning dosing, improved the sleep time–relative blood pressure decline toward a more dipper pattern without loss in 24-hour efficacy. Nocturnal BP regulation is significantly better achieved with bedtime dosing of telmisartan. Results from this prospective trial suggest that these beneficial features of bedtime dosing may be class related for angiotensin receptor blockers. These results should be taken into account when prescribing this class of antihypertensive medication for treatment of essential hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Circulation · doi:10.1161/01.cir.0000154900.76284.f6 · Cited by 3,985
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000150859.47929.8e · Cited by 2,051
O'Brien, E., Asmar, R., Beilin, L., Imai, Y., Mallion, J.-M., Mancia, G., Mengden, T., Myers, M., Padfield, P., Palatini, P., et al. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00001 · Cited by 1,655
Staessen, J. A. (1999) · JAMA · doi:10.1001/jama.282.6.539 · Cited by 1,592
Kario, K., Pickering, T. G., Umeda, Y., Hoshide, S., Hoshide, Y., Morinari, M., Murata, M., Kuroda, T., Schwartz, J. E., & Shimada, K. (2003) · Circulation · doi:10.1161/01.cir.0000056521.67546.aa · Cited by 1,250
Dolan, E., Stanton, A., Thijs, L., Hinedi, K., Atkins, N., McClory, S., Hond, E. D., McCormack, P., Staessen, J. A., & O’Brien, E. (2005) · Hypertension · doi:10.1161/01.hyp.0000170138.56903.7a · Cited by 1,227
Kikuya, M., Ohkubo, T., Asayama, K., Metoki, H., Obara, T., Saito, S., Hashimoto, J., Totsune, K., Hoshi, H., Satoh, H., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000152079.04553.2c · Cited by 417
Cited by
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2010) · Chronobiology International · doi:10.3109/07420528.2010.510230 · Cited by 608
“…increasing the sleeptime relative BP decline towards a more normal dipping pattern or with specifically reducing asleep BP, which has been found to be much more feasible by bedtime than upon-waking dosing of conventional hypertension medications (Hermida et al., 2007b), is still a matter of debate.”
BackgroundMethodResultInfluentialSelf-citationMedicine in the Fourth Dimension
Cederroth, C. R., Albrecht, U., Bass, J., Brown, S. A., Dyhrfjeld-Johnsen, J., Gachon, F., Green, C. B., Hastings, M. H., Helfrich-Förster, C., Hogenesch, J. B., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.019 · Cited by 359
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701127 · Cited by 203
Self-citationChronotherapy With Low-Dose Aspirin for Prevention of Complications in Pregnancy
Ayala, D. E., Ucieda, R., & Hermida, R. C. (2013) · Chronobiology International · doi:10.3109/07420528.2012.717455 · Cited by 203
“…enzyme inhibitors results in significantly greater therapeutic effect both on the asleep BP mean and sleep-time relative BP decline towards more of a dipping pattern, independent of the terminal half-life of the medications (Hermida & Ayala, 2009; Hermida et al., 2003e, 2007a, 2009a, 2010a, 2011a).”
BackgroundInfluentialSelf-citationHermida, R. C., Ayala, D. E., Fernandez, J. R., Portaluppi, F., Fabbian, F., & Smolensky, M. H. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2010.217 · Cited by 159
Self-citation
Metadata
- Authors
- Hermida, R. C., Ayala, D. E., Fernández, J. R., & Calvo, C.
- Venue
- Hypertension
- Published
- 2007-10
- Volume
- 50
- Issue
- 4
- Pages
- 715-722
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2100509895
- Cited by
- 134
- References
- 8
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the Efficacy of Morning Versus Evening Administration of Telmisartan in Essential Hypertension. https://app.cochat.ai/papers/10.1161/hypertensionaha.107.094235
- The paper
- Hermida, R. C., Ayala, D. E., Fernández, J. R., & Calvo, C. (2007). Comparison of the Efficacy of Morning Versus Evening Administration of Telmisartan in Essential Hypertension. Hypertension. https://doi.org/10.1161/hypertensionaha.107.094235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.